

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-002C1 (4006/13)

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001 GROUP: 1646

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|-----|--------------------|---------|---------------------|-------|--------------|-------------------------------|
| PM | A51 | 5,019,368 | 5/28/91 | Epstein et al. | | | |
| | A52 | 5,538,866 | 7/23/96 | Israeli et al. | | | |
| | A53 | 5,645,835 | 7/8/97 | Fell, Jr. et al. | | | |
| | A54 | 5,709,859 | 1/20/98 | Aruffo et al. | | | |
| | A55 | 5,807,715 | 9/15/98 | Morrison et al. | | | |
| | A56 | 5,922,685 | 7/13/99 | Rakhmilevich et al. | | | |
| | A57 | 6,277,375 B1 | 8/21/01 | Ward | | | |
| | A58 | 6,348,192 | 2/19/02 | Chan et al. | | | |
| ✓ | A59 | 6,406,689 B1 | 6/18/02 | Falkenberg et al. | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| PM | B82 | 0 318 554 | 6/7/89 | EP | | | | | Y |
| | B83 | WO 95/31483 | 11/23/95 | PCT | | | | | Y |
| | B84 | WO 99/60128 | 11/25/99 | PCT | | | | | Y |
| | B85 | WO 00/78334 | 12/28/00 | PCT | | | | | Y |
| | B86 | WO 01/10912 | 2/15/01 | PCT | | | | | Y |
| ✓ | B87 | WO 03/015697 | 2/27/03 | PCT | | | | | Y |

EXAM.
INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

| | | |
|----|------|---|
| PM | C140 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237. |
| | C141 | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831. |
| | C142 | Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518. |
| | C143 | Bissery et al., (1997), <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher Edition, Ch. 8. |
| ✓ | C144 | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415. |

EXAMINER Prema Menon

DATE CONSIDERED 11/17/03

RECEIVED
JUL 21 2003
TECH CENTER 1600/2900

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-002C1 (4006/13)

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001

GROUP: 164

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
|----------------|--|---|
| PM | C145 | Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587. |
| | C146 | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355. |
| | C147 | Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298. |
| | C148 | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713. |
| | C149 | Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:22:15552-15558. |
| | C150 | Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782. |
| | C151 | Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human Fc γ RI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338. |
| | C152 | Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60. |
| | C153 | Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004. |
| | C154 | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731. |
| | C155 | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92:3730-3736. |
| | C156 | Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Thera.</u> , 80:277-292. |
| | C157 | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994. |
| | C158 | Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:473-492. |
| | C159 | Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458. |
| | C160 | Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142. |
| | C161 | Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Res.</u> , 59:1036-1040. |
| | C162 | Roessler et al., (1994), "Cooperative Interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-bindign affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347. |

EXAMINER

Ferna Menly

DATE CONSIDERED

11/17/03

TECH CENTER 1600/2900
JUL 21 2003RECEIVED
JUL 21 2003



Sheet 3 of 3

RECEIVED
JUL 21 2003
TECH CENTER 1600/2000

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-002C1 (4006/13)

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001 GROUP: 1646

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
|----------------|--|---|
| PM | C163 | Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8.3-8.4. |
| | C164 | Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640. |
| | C165 | Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202. |
| | C166 | Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>J. Immunol.</u> , 163:5020-5028. |
| | C167 | Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Res.</u> , 60:247-267. |
| | C168 | Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:12-20. |
| | C169 | Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:3662-3672. |

EXAMINER Prema Meng

DATE CONSIDERED 11/17/03

2641025

| | | |
|---|--|---|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C RECEIVED TECH CENTER 1800/2900 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 03 MAR 10 AM 9:05 FILING DATE: December 4, 2001 GROUP: 1646 |
|---|--|---|

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|-----|--------------------|----------|------------------|-------|--------------|-------------------------------|
| PM | A1 | 07/348,237 | 5/5/89 | Rosenblum et al. | | | |
| | A2 | 4,196,265 | 4/1/80 | Koprowski et al. | | | |
| | A3 | 4,469,797 | 9/4/84 | Albarella | | | |
| | A4 | 4,676,980 | 6/30/87 | Segal et al. | | | |
| | A5 | 4,816,567 | 3/28/89 | Cabilly et al. | | | |
| | A6 | 4,946,778 | 8/7/90 | Ladner et al. | | | |
| | A7 | 5,073,627 | 12/17/91 | Curtis et al. | | | |
| | A8 | 5,114,711 | 5/19/92 | Bell et al. | | | |
| | A9 | 5,116,964 | 5/26/92 | Capon et al. | | | |
| | A10 | 5,199,942 | 4/6/93 | Gillis | | | |
| | A11 | 5,225,538 | 7/6/93 | Capon et al. | | | |
| | A12 | 5,225,539 | 7/6/93 | Winter | | | |
| | A13 | 5,258,498 | 11/2/93 | Huston et al.. | | | |
| | A14 | 5,314,995 | 5/24/94 | Fell, Jr. et al. | | | |
| | A15 | 5,349,053 | 9/20/94 | Landolfi | | | |
| | A16 | 5,514,582 | 5/7/96 | Capon et al. | | | |
| | A17 | 5,541,087 | 7/30/96 | Lo et al. | | | |
| | A18 | 5,543,297 | 8/6/96 | Cromlish, et al. | | | |
| | A19 | 5,552,524 | 09/03/96 | Basinski et al. | | | |
| | A20 | 5,585,089 | 12/17/96 | Queen et al. | | | |
| | A21 | 5,609,846 | 3/11/97 | Goldenberg | | | |
| | A22 | 5,639,725 | 6/17/97 | O'Reilly et al. | | | |
| | A23 | 5,650,150 | 7/22/97 | Gillies | | | |
| | A24 | 5,650,492 | 7/22/97 | Gately, et al. | | | |
| | A25 | 5,667,776 | 9/16/97 | Zimmerman et al. | | | |

| | |
|-----------------------------|--------------------------------|
| EXAMINER <i>Prerna Meny</i> | DATE CONSIDERED <i>6/30/03</i> |
|-----------------------------|--------------------------------|

| | | | | |
|---|--|--|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
|---|--|--|--|--|

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|-------------------------------|
| Pm | A26 | 5,691,309 | 11/25/97 | Basinski et al. | | | |
| | A27 | 5,719,266 | 02/17/98 | DiMarchi et al. | | | |
| | A28 | 5,723,125 | 3/3/98 | Chang et al. | | | |
| | A29 | 5,726,044 | 3/10/98 | Lo et al. | | | |
| | A30 | 5,728,552 | 3/17/98 | Fujisawa et al. | | | |
| | A31 | 5,733,876 | 3/31/98 | O'Reilly et al. | | | |
| | A32 | 5,756,461 | 05/26/98 | Stephens | | | |
| | A33 | 5,759,551 | 6/2/98 | Ladd et al. | | | |
| | A34 | 5,770,195 | 6/23/98 | Hudziak et al. | | | |
| | A35 | 5,800,810 | 9/1/98 | Doyle et al. | | | |
| | A36 | 5,827,516 | 10/27/98 | Urban et al. | | | |
| | A37 | 5,837,682 | 11/17/98 | Folkman et al. | | | |
| | A38 | 5,843,423 | 12/1/98 | Lyman et al. | | | |
| | A39 | 5,854,205 | 12/29/98 | O'Reilly et al. | | | |
| | A40 | 5,858,347 | 1/12/99 | Bauer et al. | | | |
| | A41 | 5,885,795 | 3/23/99 | O'Reilly et al. | | | |
| | A42 | 5,886,178 | 3/23/99 | Allen et al. | | | |
| | A43 | 5,908,626 | 6/1/99 | Chang et al. | | | |
| | A44 | 5,994,126 | 11/30/99 | Steinman et al. | | | |
| | A45 | 6,080,409 | 6/27/00 | Laus et al. | | | |
| | A46 | 6,086,875 | 7/11/00 | Blumberg et al. | | | |
| | A47 | 6,100,387 | 8/8/00 | Herrmann et al. | | | |
| | A48 | 6,169,070 | 1/2/01 | Chen et al. | | | |
| | A49 | 6,171,588 | 1/9/01 | Carron et al. | | | |
| ↓ | A50 | 5,359,035 | 10/25/94 | Habermann | | | |

| | |
|----------------------------|--------------------------------|
| EXAMINER <i>Prema Meng</i> | DATE CONSIDERED <i>6/30/03</i> |
|----------------------------|--------------------------------|

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 | | | | |
|---|--|--|--|--|--|--|--|--|

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILIN G DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|--------------------|---|--------------------------|
| PM | B1 | 0 158 198 | 10/16/85 | EP | | | | | Y |
| | B2 | 0 211 769 | 2/25/87 | EP | | | | | Y |
| | B3 | 0 256 714 | 2/24/88 | EP | | | | | Y |
| | B4 | 0 294 703 | 12/14/88 | EP | | | | | Y |
| | B5 | 0 308 936 | 3/29/89 | EP | | | | | Y |
| | B6 | 0 314 317 | 5/3/89 | EP | | | | | Y |
| | B7 | 0 319 012 | 6/7/89 | EP | | | | | Y |
| | B8 | 0 326 120 | 4/15/98 | EP | | | | | Y |
| | B9 | 0 350 230 | 1/10/90 | EP | | | | | Y |
| | B10 | 0 375 562 | 6/27/90 | EP | | | | | Y |
| | B11 | 0 396 387 | 11/7/90 | EP | | | | | Y |
| | B12 | 0 439 095 | 7/31/91 | EP | | | | | Y |
| | B13 | 0 511 747 | 11/4/92 | EP | | | | | Y |
| | B14 | 0 601 043 | 11/25/98 | EP | | | | | Y |
| | B15 | 0 706 799 | 4/17/96 | EP | | | | | Y |
| | B16 | 0 790 309 | 8/20/97 | EP | | | | | Y |
| | B17 | 21725/88 | 3/23/89 | AU | | | | | Y |
| | B18 | 93100115.3 | 7/14/93 | CN | | | | B77 is English abstract | N |
| | B19 | 37 12985 | 11/3/88 | DE | | | | B78 is English abstract; A50 is English counterpart | N |
| | B20 | 2 292 382 | 2/21/96 | GB | | | | | Y |
| | B21 | 63-267278 | 11/4/88 | JP | | | | B79 is English abstract | N |
| | B22 | 63-267296 | 11/4/88 | JP | | | | B80 is English abstract; B81 is English counter part | N |
| | B23 | WO 86/01533 | 3/13/86 | PCT | | | | | Y |
| | B24 | WO 88/00052 | 1/14/88 | PCT | | | | | Y |

| | | | |
|----------|-------------|-----------------|---------|
| EXAMINER | Premna Meny | DATE CONSIDERED | 6/30/03 |
|----------|-------------|-----------------|---------|

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 | | | | |
|---|--|--|--|--|--|--|--|--|

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILIN G DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|--------------------|------------------------|--------------------------|
| PM | B25 | WO 88/09344 | 12/1/88 | PCT | | | | | Y |
| | B26 | WO 89/02922 | 4/6/89 | PCT | | | | | Y |
| | B27 | WO 89/09620 | 10/19/89 | PCT | | | | Abstract in English | N |
| | B28 | WO 90/03801 | 4/19/90 | PCT | | | | | Y |
| | B29 | WO 91/00360 | 1/10/91 | PCT | | | | | Y |
| | B30 | WO 91/04329 | 04/04/91 | PCT | | | | | Y |
| | B31 | WO 91/08298 | 6/13/91 | PCT | | | | | Y |
| | B32 | WO 91/13166 | 9/5/91 | PCT | | | | | Y |
| | B33 | WO 91/14438 | 10/3/91 | PCT | | | | | Y |
| | B34 | WO 92/02240 | 2/20/92 | PCT | | | | | Y |
| | B35 | WO 92/08495 | 5/29/92 | PCT | | | | | Y |
| | B36 | WO 92/08801 | 5/29/92 | PCT | | | | | Y |
| | B37 | WO 92/16562 | 10/1/92 | PCT | | | | | Y |
| | B38 | WO 93/03157 | 2/18/93 | PCT | | | | | Y |
| | B39 | WO 93/10229 | 5/27/93 | PCT | | | | | Y |
| | B40 | WO 95/05468 | 2/23/95 | PCT | | | | | Y |
| | B41 | WO 95/21258 | 8/10/95 | PCT | | | | | Y |
| | B42 | WO 95/28427 | 10/26/95 | PCT | | | | | Y |
| | B43 | WO 96/04388 | 02/15/96 | PCT | | | | | Y |
| | B44 | WO 96/05309 | 2/22/96 | PCT | | | | | Y |
| | B45 | WO 96/08570 | 3/21/96 | PCT | | | | | Y |
| | B46 | WO 96/18412 | 6/20/96 | PCT | | | | | Y |
| | B47 | WO 96/31526 | 10/10/96 | PCT | | | | | Y |
| | B48 | WO 97/00317 | 9/18/97 | PCT | | | | | Y |
| ↓ | B49 | WO 97/00319 | 1/3/97 | PCT | | | | | Y |

| | | | |
|----------|------------|-----------------|---------|
| EXAMINER | Prima Mung | DATE CONSIDERED | 6/21/03 |
|----------|------------|-----------------|---------|

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 | | | | |
|---|--|--|--|--|--|--|--|--|

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| Pm | B50 | WO 97/15666 | 5/1/97 | PCT | | | | | Y |
| | B51 | WO 97/20062 | 6/5/97 | PCT | | | | | Y |
| | B52 | WO 97/24137 | 7/10/97 | PCT | | | | | Y |
| | B53 | WO 97/24440 | 7/10/97 | PCT | | | | | Y |
| | B54 | WO 97/26335 | 7/24/97 | PCT | | | | | Y |
| | B55 | WO 97/30089 | 8/21/97 | PCT | | | | | Y |
| | B56 | WO 97/33617 | 9/18/97 | PCT | | | | | Y |
| | B57 | WO 97/33619 | 1/3/97 | PCT | | | | | Y |
| | B58 | WO 97/34631 | 9/25/97 | PCT | | | | | Y |
| | B59 | WO 98/00127 | 1/8/98 | PCT | | | | | Y |
| | B60 | WO 98/06752 | 2/19/98 | PCT | | | | | Y |
| | B61 | WO 98/28427 | 7/2/98 | PCT | | | | | Y |
| | B62 | WO 98/30706 | 7/16/98 | PCT | | | | | Y |
| | B63 | WO 98/46257 | 10/98 | PCT | | | | | Y |
| | B64 | WO 98/59244 | 12/30/98 | PCT | | | | | Y |
| | B65 | WO 99/02709 | 01/21/99 | PCT | | | | | Y |
| | B66 | WO 99/03887 | 01/28/99 | PCT | | | | | Y |
| | B67 | WO 99/29732 | 6/17/99 | PCT | | | | | Y |
| | B68 | WO 99/43713 | 9/2/99 | PCT | | | | | Y |
| | B69 | WO 99/52562 | 10/21/99 | PCT | | | | | Y |
| | B70 | WO 99/53958 | 10/28/99 | PCT | | | | | Y |
| | B71 | WO 99/62944 | 12/09/99 | PCT | | | | | Y |
| | B72 | WO 00/11033 | 3/2/00 | PCT | | | | | Y |
| | B73 | WO 00/34317 | 06/15/00 | PCT | | | | | Y |
| | B74 | WO 00/40615 | 7/13/00 | PCT | | | | | Y |

EXAMINER *Prerna Mehta* DATE CONSIDERED *6/30/03*

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 | | | | |
|---|--|--|--|--|--|--|--|--|

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|----------------------------|--------------------------|
| PM | B75 | WO 00/69913 | 11/23/02 | PCT | | | | | Y |
| | B76 | WO 01/07081 | 2/1/01 | PCT | | | | | Y |
| | B77 | 93100115.3 | 7/14/93 | CN | | | | English abstract of B18 | Y |
| | B78 | 37 12985 | 11/3/88 | DE | | | | English abstract of B19 | Y |
| | B79 | 63-267278 | 11/4/88 | JP | | | | English abstract of B21 | Y |
| | B80 | 63-267296 | 11/4/88 | JP | | | | English abstract of B22 | Y |
| ↓ | B81 | 0 237 019 | 9/16/87 | EP | | | | English counterpart of B22 | Y |

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
|----------------|--|---|--|
| PM | C1 | Abaza et al., (1992) "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization" <u>Journal of Protein Chemistry</u> , Vol. 11, No. 5: pp. 433-444. | |
| | C2 | Abstract XP-002116766, (1996) "Prostaglandins, their inhibitors and cancer" <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , Vol. 54, No. 2, pp. 83-94. | |
| | C3 | Arenberg et al. (1996) "Interferon-γ-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , Vol. 184, pp. 981-992. | |
| | C4 | Bacha et al., (1988). "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", <u>J. Experimental Medicine</u> , Vol. 167, pp. 612-622 | |
| | C5 | Bachelot et al., (March 1998) "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , Vol. 39, pp. 271, Abstract #1856. | |
| | C6 | Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139. | |
| ↓ | C7 | Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." <u>Cancer Research</u> , Vol. 58, pp. 2825-2831. | |

| | |
|-----------------------------|--------------------------------|
| EXAMINER <i>Premma Meek</i> | DATE CONSIDERED <i>6/30/03</i> |
|-----------------------------|--------------------------------|

| | | |
|---|---|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C8 | Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , Vol. 5, No. 12, pp. 4259-4263. |
| | C9 | Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 2702-2707. |
| | C10 | Beutler et al., (1988) "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", <u>Ann. Rev. Biochem.</u> , Vol. 57, pp. 505-518. |
| | C11 | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" <u>Cancer Research</u> , Vol. 45, pp. 1214-1221. |
| | C12 | Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Letters to Nature</u> , Vol. 390, pp. 404-407. |
| | C13 | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , Vol. 252, pp. 190-194. |
| | C14 | Brooks et al. (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , Vol. 79, pp. 1157-1164. |
| | C15 | Burgess et al., (1990), "Possible Dissociation of the heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , Vol. 111, pp. 2129-2138. |
| | C16 | Canfield et al. (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , Vol. 173, No. 6, pp. 1483-1491. |
| | C17 | Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 46, pp. 29461-29467. |
| | C18 | Cao et al. (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 36, pp. 22924-22928. |
| | C19 | Capon et al. (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , Vol. 337, pp. 525-531. |
| | C20 | Chan et al., (1991) "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879. |
| | C21 | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , Vol. 5, pp. 385-90. |
| ↓ | C22 | Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin" <u>Nature</u> , Vol. 339, pp. 394-397. |
| EXAMINER | Prem Mehta | DATE CONSIDERED 6/30/03 |

| | | |
|---|---|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C23 | Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , Vol. 335, pp. 370-372. |
| | C24 | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , Vol. 159, No. 1, pp. 351-358. |
| | C25 | Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> 91: 989-993. |
| | C26 | Cohen, S. L. et al., (August 15, 1996), "Human leptin characterization," <u>Nature</u> , Vol. 382, p. 589. |
| | C27 | Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , Vol. 159, pp. 3613-3621. |
| | C28 | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , Vol. 56, pp. 2531-2534. |
| | C29 | D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 4082-4085. |
| | C30 | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , Vol. 176, pp. 1387-1398. |
| | C31 | Ding et al., (September 1988), "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , Vol. 95, No. 18, pp. 10443-10448. |
| | C32 | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , Vol. 161, pp. 156-166. |
| | C33 | Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> Vol. 31, pp. 342-348. |
| | C34 | Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , Vol. 146, pp. 2446-2452. |
| | C35 | Friedman, J. M. et al., (October 22, 1998). "Leptin and the regulation of body weight in mammals," <u>Nature</u> , Vol. 395, pp. 763-770. |
| | C36 | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils", <u>Science</u> , Vol. 226, pp. 1339-134. |
| | C37 | Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 495-521. |
| | C38 | Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" <u>Eur. J. Immunol.</u> , Vol. 25, pp. 200-206. |
| EXAMINER | Penna Menk | DATE CONSIDERED |

| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
|---|--|---|
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C39 | Gillies et al. (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> Vol. 1, No. 1, pp. 47-54. |
| | C40 | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , Vol. 125, pp. 191-202. |
| | C41 | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , Vol. 89, pp. 1428-1432. |
| | C42 | Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , Vol. 4, pp. 230-235. |
| | C43 | Gillies, et al., (June 1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>Journal Immunology</u> , Vol. 160, No. 12, pp. 6195-6203. |
| | C44 | Gillies, et al., (1999 May), "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors," <u>Cancer Research</u> , Vol. 59, No. 9, pp 2159-2166. |
| | C45 | Gillies et al., (1989), "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , Vol. 7, pp. 799-804. |
| | C46 | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , Vol. 120, No. 6, pp. 2027-2032. |
| | C47 | Goeddel et al., (1986), "Tumor Necrosis Factors; Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609. |
| | C48 | Gren et al., (1983), "A New Type of Leukocytic Interferon," .. <u>Dokl. Biochem.</u> , Vol. 269, pp. 91-95. |
| | C49 | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , Vol. 73, No. 8, pp. 2081-2805. |
| | C50 | Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> Vol. 45, pp. 146-148. |
| | C51 | Harris et al., "Therapeutic Antibodies - the Coming of Age" <u>Tibtech</u> , 11:42-44 (Feb. 1993). |
| | C52 | Harvill et al. (1996 October), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation." <u>Journal of Immunology</u> , Vol. 157, No. 7, pp. 3165-3170. |
| | C53 | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , Vol. 11, Issue 6, pp. 629-636. |
| | C54 | He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> 1029-1035. |
| ↓ | C55 | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers" In Vivo Biology of IL-12 p40 Homodimer," <u>Journal of Immunology</u> , Vol. 158, pp. 4381-4388. |
| EXAMINER | Penna Mung | DATE CONSIDERED 6/30/03 |

| | | |
|---|---|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C56 | Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 83, No. 18, pp. 7059-7063. |
| | C57 | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , Vol. 3, pp. 31-58. |
| | C58 | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , Vol. 7, No. 2, pp. 159-167. |
| | C59 | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 Å Resolution," <u>EMBO Journal</u> , Vol. 17, No. 6, pp. 1656-1664. |
| | C60 | Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, p. 683. |
| | C61 | Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" <u>Clinical Cancer Research</u> ; Vol. 7, No. 9, pp. 2862-2869. |
| | C62 | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , Vol. 1096, No. 4, pp. :345-354 (Abstract). |
| | C63 | Hoogenboom et al., (1991), "Constriction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , Vol. 28, No. 9, pp. 1027-1037 |
| | C64 | Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14, No. 4, pp. 1779-1789. |
| | C65 | Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , Vol. 246, pp. 1275-1281. |
| | C66 | Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , Vol. 348, pp. 555-557. |
| | C67 | Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , Vol. 321, No. 6069, pp. 522-525. |
| | C68 | Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 4479-4483. |
| | C69 | Junghans et al. (1996) "The protection receptor of IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, No. 11, pp. 5512-5516. |
| | C70 | Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88, pp. 11120-11123. |
| EXAMINER | Premma Menon | DATE CONSIDERED 6/30/03 |

| | | |
|---|---|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C71 | Kappel, et al. (1992) "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553 |
| | C72 | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc λ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , Vol. 160, No. 6, pp. 1686-1701. |
| | C73 | Kendra et al., (1999), "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol. Immunotherapy</u> , Vol. 48, pp. 219-229. |
| | C74 | Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" <u>Journal of Interferon and Cytokine Research</u> , Vol. 19, pp. 77-84. |
| | C75 | Kim, et al., (May 1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." <u>Journal Immunology</u> , Vol. 158, No. 9, pp. 4137-4144. |
| | C76 | Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 81, 7922-7926. |
| | C77 | Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , Vol. 152, No. 6, pp. 1233-1246. |
| | C78 | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , Vol. 268, No. 31, pp. 23311-23317. |
| | C79 | Lazar et al., (1988), "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> Vol. 8, No. 3, pp. 1247-1252. |
| | C80 | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , Vol. 51, pp. 2694-2698. |
| | C81 | Lieschke, et al., (January 1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." <u>Nature Biotechnology</u> , Vol. 15, No. 1, pp. 35-40. |
| | C82 | Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , Vol. 174, No. 3, pp. 561-569. |
| | C83 | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , Vol. 239, pp. 395-398. |
| | C84 | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp. 8648-8652. |
| | C85 | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells" <u>Protein Engineering</u> , Vol. 11, No. 6, pp. 495-500. |
| ↓ | C86 | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , Vol. 91, No. 5, pp. 1706-1715. |
| EXAMINER | Premma Menon | DATE CONSIDERED |

| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
|---|--|---|
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C87 | Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v -antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 1591-1596. |
| | C88 | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , Vol. 29, No. 2, pp. 117-120. |
| | C89 | Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 8591-8596. |
| | C90 | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , Vol. 84, No. 8, pp. 2457-2466. |
| | C91 | Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> Vol. 25, pp. 137-146. |
| | C92 | Mark et al., (December 1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins." <u>Journal of Biological Chemistry</u> , Vol. 267, No. 36, pp. 26166-26171. |
| | C93 | Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 ¹ ," <u>Journal Immunology</u> , Vol. 158, No. 5, pp. 2211-2217. |
| | C94 | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , Vol. 57, pp. 2890-2895. |
| | C95 | Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> Vol. 7, pp. 145-173. |
| | C96 | Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 8258-8262. |
| | C97 | Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , pp. 123-140. |
| | C98 | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , Vol. 13, No. 17, pp. 6361-6373. |
| | C99 | Neuberger, et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , Vol. 312, pp. 604-608. |
| | C100 | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , Vol. 79, pp. 315-328. |
| | C101 | O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , Vol. 2, No. 6, pp. 689-692. |
| | C102 | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , Vol. 88 pp. 277-285. |
| EXAMINER <i>Penna Meng</i> | | DATE CONSIDERED <i>6/30/03</i> |

| | | |
|---|--|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
|---|--|--|

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
|----------------|--|---|
| PM | C103 | Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins", <u>Journal of Biological Chemistry</u> , Vol. 264, No. 26, pp. 15157-15160. |
| | C104 | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , Vol. 6, pp. 407-438. |
| | C105 | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , Vol. 163, pp. 166-178. |
| | C106 | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal Immunology</u> , Vol. 142, No. 10, pp. 3662-3667. |
| | C107 | Putzer et al. (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , Vol. 94, pp. 10889-10894. |
| | C108 | Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunolgy</u> , pp. 27-53. |
| | C109 | Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , Vol. 7. Suppl. 2, pp. S99-S106. |
| | C110 | Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , Vol. 343, pp. 1177-1183. |
| | C111 | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , Vol. 9, No. 2, pp. 58-62. |
| | C112 | Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> 2, Vol. 2, No. 3, pp. 159-173. |
| | C113 | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , Vol. 46, pp. 4701-4705. |
| | C114 | Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , Vol. 17, No. 15, pp. 4249-4256. |
| | C115 | Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 84, pp. 6904-6908. |
| | C116 | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , Vol. 148, No. 11, pp. 3433-3340. |
| | C117 | Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 85, No. 13, pp. 4842-4846. |
| ↓ | C118 | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon-λ and is not blocked by human IgG," <u>Journal of Immunology</u> , Vol. 137, No. 11, pp. 3378-3382. |

| | | | |
|----------|--------------------|-----------------|----------------|
| EXAMINER | <i>Prerna Menk</i> | DATE CONSIDERED | <i>6/30/03</i> |
|----------|--------------------|-----------------|----------------|

| | | |
|---|---|--|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| PM | C119 | Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , Vol. 96, pp. 491-503. |
| | C120 | Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 5322-5326. |
| | C121 | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , Vol. 57, pp. 1329-1334. |
| | C122 | Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," <u>Journal of Immunology</u> , Vol. 158, pp. 2242-2250. |
| | C123 | Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , Vol. 302, pp. 305-309. |
| | C124 | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , Vol. 143, No. 8, pp. 2595-2601. |
| | C125 | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , Vol. 178, No. 2, pp. 661-667. |
| | C126 | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , Vol. 57, pp. 920-925. |
| | C127 | <u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 th ed. 1999). |
| | C128 | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , Vol. 48, No. 5, pp. 1119-1123 |
| | C129 | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , Vol. 242, pp. 1166-1168 |
| | C130 | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , Vol. 84, pp. 4008-4027. |
| | C131 | Vagiani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , Vol. 56, pp. 467-470. |
| | C132 | Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , Vol. 44, pp. 681-687. |
| | C133 | Verhoeven et al. (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> 239:1534-1536. |
| EXAMINER | Premma Menon | DATE CONSIDERED |

| | | |
|---|---|---|
| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-002C1 APPLICANT(S): Gillies et al. SERIAL NO.: 10/005,212 FILING DATE: December 4, 2001 GROUP: 1646 |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| <i>PM</i> | C134 | Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", <u>Protein Engineering</u> , Vol. 1, No. 6, pp. 493-498. |
| | C135 | Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , Vol. 43, pp. 319-324. |
| | C136 | Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunol.</u> 151: 6602-6607. |
| | C137 | Wu et al., (July 1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin", <u>Biochemical and Biophysical Research Communications</u> , Vol. 236, No. 3, pp. 651-654. |
| | C138 | Xiang et al. (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , Vol. 57, pp. 4948-4955. |
| | C139 | Xin Xau Zheng, et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogenic islet transplantation." <u>Journal Immunology</u> , Vol. 154, No. 10, pp 5590-5600. |
| EXAMINER | <i>Prerna Meng</i> | |
| | DATE CONSIDERED | <i>6/30/03</i> |

2578831